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Introduction 
Heme is an iron-protoporphyrin complex that plays a cen-
tral role in oxygen and electron transfer, and is an important
functional group in various proteins, for example myoglobin
and hemoglobin. As such, heme is critical to oxygen trans-
port, drug metabolism, respiration and signal transduction.1
Free heme is liberated from hemoglobin released from lysed
red blood cells in several pathological states, including bacte-
rial infections, hemolytic anemias, and hemoglobinopathies.1
The plasma proteins haptoglobin and hemopexin scavenge
hemoglobin and heme, respectively, and clear them from the
blood.2 Unfortunately, these protective mechanisms can
become overwhelmed in many pathological states, resulting
in complete depletion of hemopexin and very high levels of
free heme in the blood.1,3 For example, in sickle cell disease
patients, chronic hemolysis results in steady state blood heme
levels around 4 mM, but these levels can reach 20 mM in some
patients.4
An excess of free heme is highly toxic, because it catalyzes
the formation of reactive oxygen species (ROS), leading to
oxidative stress and cell injury.1,5,6 Free heme is highly
lipophilic and can intercalate in the lipid membranes of the
vascular endothelium. These two processes result in endothe-
lial cell (EC) activation, recruiting leukocytes to the endothe-
lium, and initiating an inflammatory response that damages
the endothelium and increases vascular permeability.5
Tissue factor (TF) is the primary initiator of the extrinsic
coagulation cascade, and the TF:FVIIa complex activates both
FX and FIX, resulting in thrombin generation, fibrin deposi-
tion and platelet activation.7 TF is constitutively expressed by
perivascular cells and is sequestered from the blood, but upon
tissue injury it can initiate clotting.8 Inducible TF expression is
also observed on monocytes in various pathological condi-
tions, including sepsis9,10 and sickle cell disease.11,12 Heme has
been demonstrated to induce TF expression and activity on
endothelial cells in vitro.13 Furthermore, TF expression has been
observed on the lung endothelium in mouse models of sickle
cell disease.14,15 We previously demonstrated that, in mouse
models of sickle cell disease, TF contributes to both coagula-
tion activation and vascular inflammation.14 
In this study, we investigated the mechanism by which
excess of free heme contributes to the activation of coagula-
tion in a mouse model of heme overload.  
Methods
Mice 
Male and female C57BL/6J mice (10-12 weeks old) were used for
dose response and time course studies. Generation of TFflox/flox, Tie-2
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An excess of free heme is present in the blood during many types of hemolytic anemia.  This has been linked to
organ damage caused by heme-mediated oxidative stress and vascular inflammation. We investigated the mech-
anism of heme-induced coagulation activation in vivo. Heme caused coagulation activation in wild-type mice that
was attenuated by an anti-tissue factor antibody and in mice expressing low levels of tissue factor. In contrast, nei-
ther factor XI deletion nor inhibition of factor XIIa-mediated factor XI activation reduced heme-induced coagula-
tion activation, suggesting that the intrinsic coagulation pathway is not involved. We investigated the source of
tissue factor in heme-induced coagulation activation. Heme increased the procoagulant activity of mouse
macrophages and human PBMCs. Tissue factor-positive staining was observed on leukocytes isolated from the
blood of heme-treated mice but not on endothelial cells in the lungs. Furthermore, heme increased vascular per-
meability in the mouse lungs, kidney and heart. Deletion of tissue factor from either myeloid cells, hematopoietic
or endothelial cells, or inhibition of tissue factor expressed by non-hematopoietic cells did not reduce heme-
induced coagulation activation. However, heme-induced activation of coagulation was abolished when both non-
hematopoietic and hematopoietic cell tissue factor was inhibited. Finally, we demonstrated that coagulation acti-
vation was partially attenuated in sickle cell mice treated with recombinant hemopexin to neutralize free heme.
Our results indicate that heme promotes tissue factor-dependent coagulation activation and induces tissue factor
expression on leukocytes in vivo. We also demonstrated that free heme may contribute to thrombin generation in
a mouse model of sickle cell disease.   
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ABSTRACT
Cre + and TFflox/flox, LysM Cre+ mice,16 low TF mice (mTF–/–, hTF+)
and heterozygous littermate controls (mTF+/–, hTF+),17 and FXI–/–
mice18 have been previously described. Human TF (HTF) mice,
expressing no mouse TF but normal levels of human TF, have also
been previously described.19 To generate human-mouse TF
chimeras, C57Bl/6J mice were lethally irradiated with two doses
of 7 Gγ (4 h apart) with a 137Cs irradiator (Mark I Irradiator, J. L.
Shepherd & Associates) then injected with bone marrow (BM) (4-
5 x 106 nucleated cells) from HTF mice via the retro-orbital (RO)
sinus. These mice, referred to as HTFBM/WT, express human TF on
hematopoietic cells and mouse TF on all non-hematopoietic cells.
Mice recovered for 12 weeks before heme treatment. All animal
studies were approved by the University of North Carolina
Animal Care and Use Committees and complied with National
Institutes of Health guidelines. 
Preparation and administration of heme
Porcine heme (Sigma Aldrich, St. Louis, MO, USA) was prepared
at 25 mM in 0.1M NaOH and 0.1M Tris-HCl (final pH 8.0), sterile
filtered (0.22 mm) and diluted to 10 mM in saline. Vehicle buffer was
prepared by diluting sterile-filtered 0.1M NaOH and 0.1M Tris-HCl
(pH=8.0) in saline. Mice were anesthetized with isoflurane, and
administered heme via RO injection at doses from 0-35 mmol/kg.5
These doses are based on the predicted molarity of heme in blood
based on the estimated blood volume of the mouse.20 
Administration of antibodies
C57Bl/6J mice were treated with rat anti-mouse TF (1H1) or
control rat IgG antibodies (20 mg/kg) by intraperitoneal injection
30 min before heme administration.16 1H1 is a monoclonal rat
anti-mouse TF antibody that competes for binding of factor VII.21
Chimeric HTFBM/WT mice were administered anti-human TF
(HTF1, 10 mg/kg), anti-mouse TF (1H1, 20 mg/kg) or control IgG
(10 mg/kg) 30 min before heme.22 To inhibit the intrinsic coagula-
tion pathway, C57BI/bJ mice were treated with mouse IgG or the
murine monoclonal antibody 14E11 (6 mg/kg) via intraperitoneal
(IP) injection 30 min before heme administration. This antibody
inhibits FXIIa-dependent activation of FXI and had an anticoagu-
lant effect in a mouse model of sepsis.23,24 
Hemopexin treatment of sickle cell mice
We used the Berkley mouse as a model of sickle cell disease.25
Human hemopexin (Athens Research Technology, Athens, GA,
USA) (500 mg in 100 mL PBS per 25 gram of body weight; 280
mmol/kg) was administered to 5-month old male mice via tail vein
injection twice a week for two weeks. 
Sample collection and analysis
Mice were anesthetized by isoflurane, and blood was drawn
from the inferior vena cava (IVC) into syringes containing 3.8%
sodium citrate (final ratio 9:1) and centrifuged at 4000 x g for 15
min at 4ºC. Plasma was collected and immediately stored at -80ºC.
Thrombin-antithrombin (TAT) complexes were analyzed using an
ELISA kit (Enzygost TAT micro, Siemens Healthcare Diagnostics,
Malvern, PA, USA).
Analysis of procoagulant activity and TF staining
Isolation of human PBMCs and mouse white blood cells, the 
1-stage clotting assay and TF staining are standard procedures in
our laboratory,14,26 and are described in detail in the Online
Supplementary Methods. 
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5
(GraphPad Software, San Diego, CA, USA). All data are presented
as mean plus or minus SEM. For 2-group comparisons of paramet-
ric data, Student t-test was performed. For comparisons of more
than two groups, one- or two-way ANOVA with Bonferroni post
hoc analysis were performed. Non-normally distributed data were
analyzed via Kruskal-Wallis test followed by Wilcoxon-Mann
Whitney post hoc analysis. P<0.05 was considered significant for all
experiments. 
Results
Heme causes a dose- and time-dependent activation of
coagulation in wild-type mice 
Circulating levels of hemopexin in wild-type mice are
very high (0.5-1.2 g/L) and provide protection against free
heme.27 In contrast, in sickle cell mice, plasma levels of
hemopexin are significantly reduced.28 To study the contri-
bution of free heme to the activation of coagulation, we
first determined the minimal amount of heme required to
deplete hemopexin levels in wild-type mice. We found
that neither 3.5 mmol/kg nor 17.5 mmol/kg heme affected
plasma levels of hemopexin, whereas injection of 
35 mmol/kg of heme resulted in almost complete depletion
of hemopexin in the plasma 6 h after injection (Figure 1A
and B). This observation is consistent with previously
reported effects of high doses of heme on plasma levels of
hemopexin.6 Importantly, heme increased plasma levels of
TAT in a dose-dependent manner with the highest admin-
istered dose (35 mmol/kg) producing a 2.7-fold increase in
TAT levels over control (Figure 1C). All further experi-
ments were performed with the 35 mmol/kg dose of heme.
In a time course experiment, 35 mmol/kg heme caused sig-
nificant coagulation activation as early as 
1 h after administration, which was maintained through-
out the course of the experiment (Figure 1D). 
Heme-mediated coagulation activation is dependent on
the extrinsic but not the intrinsic pathway
To determine the role of TF in heme-dependent coagu-
lation activation, we used the rat anti-mouse TF blocking
antibody 1H1. Mice were treated with rat IgG or 1H1 (25
mg/kg, IP) 30 min prior to heme injection (35 mmol/kg,
RO). Inhibition of TF with 1H1 attenuated coagulation
activation in heme-treated mice (Figure 2A). As an inde-
pendent approach, we used low TF mice that expressed
very low levels of human TF (1% of wild-type levels) but
not mouse TF (mTF-/-, HTF+). Similar to anti-TF antibody-
treated mice, plasma TAT levels were significantly
reduced in heme injected low TF mice compared to con-
trols (mTF+/-, HTF+) (Figure 2B). 
Next, we investigated if the intrinsic pathway con-
tributes to heme-mediated activation of coagulation.
Thirty minutes prior to heme administration, wild-type
mice were treated with either mouse IgG or the murine
monoclonal antibody 14E11 (6 mg/kg, IP), which blocks
FXIIa-dependent activation of FXI.24 Coagulation activa-
tion was not attenuated in 14E11-treated mice (Figure 2C).
Furthermore, FXI-deficient mice were not protected from
heme-induced coagulation activation (Figure 2D). 
Heme induces TF expression on leukocytes 
Tissue factor expression has been observed in leuko-
cytes isolated from sickle cell patients11 and sickle cell
mice.14 Therefore, we determined if heme can induce TF
expression on leukocytes. RAW 264.7 mouse
macrophages were treated with various concentrations of
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heme (0-50 mM) for 6 h. Heme caused a dose-dependent
increase of procoagulant activity (PCA) in RAW 264.7 cells
(Figure 3A). PCA was also increased in human PBMCs
(Figure 3B). Furthermore, using immunohistochemistry,
we analyzed TF protein expression on leukocytes isolated
from vehicle or heme-treated mice. We observed TF posi-
tive leukocytes isolated from the blood of heme-treated
mice but not control mice (Figure 3C). In addition, positive
TF staining was observed on human PBMCs treated with
heme in vitro (Figure 3D). Based on the morphology, TF-
positive staining was observed in both monocytes and
neutrophils.
Moreover, we analyzed whether heme induces TF
expression in lung endothelial cells.
Immunohistochemistry revealed TF-positive staining in
epithelial and perivascular cells in both control and heme-
treated mice, but we did not observe TF staining on
endothelial cells in any vessels in the lung using this
method (Figure 4). Perivascular TF can be exposed to cir-
culating clotting factors as a result of vascular damage. To
determine whether heme damages the vascular endotheli-
um, we measured vascular permeability using the Evans
Blue method. In heme-treated mice, we observed an
increase in vascular permeability in the heart (1.6±0.2-fold
vs. control; P=0.041), lung (2.4±0.6-fold vs. control;
P=0.026), and kidney (1.3±0.2; P=0.05), but not liver, con-
sistent with previous reports.6 
Contribution of different cellular sources of TF to the
heme-induced coagulation activation 
To determine the cellular source of TF contributing to
heme-induced activation of coagulation, we first analyzed
the effect of TF deletion in myeloid cells. TFflox/flox, LysM
Cre+ and control TFflox/flox mice were injected with heme
and plasma TAT levels were analyzed 6 h after injection.
We found that deletion of TF from myeloid cells had no
effect on heme-dependent activation of coagulation
(Figure 5A). Plasma TAT levels were also not attenuated in
E.M. Sparkenbaugh et al.
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Figure 1. Heme depletes plasma hemopexin levels
and activates coagulation. C57BL6/J mice were
administered vehicle or heme via retroorbital injec-
tion and plasma was collected. (A) Quantification of
plasma hemopexin levels 6 h after the injection of the
indicated dose of heme (n=4 per group). Data repre-
sents fold change versus untreated mice. 
(B) Representative western blot of plasma hemopexin
(H). Blots were stained for Coomassie (C) as a loading
control. (C) Dose response of coagulation activation
as measured by thrombin-antithrombin (TAT) 6 h after
various doses of heme (n=4-5/group). 
(D) Plasma TAT levels measured 1, 3 or 6 h after injec-
tion of 35 mmol/kg of heme (n=5-10/group). Data are
presented as mean±SEM. *P<0.05, **P<0.01,
***P<0.001.
Figure 2. Heme dependent coagulation activa-
tion requires tissue factor (TF). (A) Plasma TAT
levels in C57BL6/J mice 6 h after vehicle (gray
bars) or heme (black bars, 35 mmol/kg) injec-
tion (n=5-9). Control rat IgG or 1H1 antibody
(25 mg/kg, IP) were injected 30 min prior to
heme injection. (B) Plasma TAT levels in control
(mTF+/-, hTF+) or low TF (mTF-/-, hTF+) mice 6
hours after heme injection (n=9-12). 
(C) Plasma TAT levels in C57BL6/J mice 6 h
after vehicle (gray bars) or heme (black bars,
35 µmol/kg) injection (n=5-9). Control mouse
IgG or 14E11 antibody (6 mg/kg, IP) were
injected 30 min prior to heme injection (n=6-
10). (D) Plasma TAT levels 6 h after administra-
tion of vehicle or heme in C57BL6/J or FXI-/-
mice (n=5). Data are presented as mean±SEM.
*P<0.05, **P<0.01, ***P<0.001. Asterisks
over bar indicate significance versus respective
vehicle-treated control; asterisks over line indi-
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heme-injected TFflox/flox, Tie2 Cre+ mice in which the TF
gene is deleted in both hematopoietic cells and endothelial
cells (Figure 5B). 
Since heme-induced vascular permeability may result in
the exposure of perivascular TF to circulating factor
VII/VIIa, we next investigated the contribution of this
source of TF to heme-induced activation of coagulation.
We generated chimeric mice that express human TF on
hematopoietic cells and murine TF on non-hematopoietic
cells (WT recipient mice with bone marrow from HTF
mice) and used species-specific antibodies to target the
different sources of TF. Mice were treated with either IgG,
1H1 or a combination of 1H1 and HTF-1 (mouse anti-
human TF antibody) antibodies. Interestingly, inhibition
of non-hematopoietic TF with 1H1 had no effect on
heme-mediated coagulation activation. However, combin-
ing 1H1 and HTF-1, to block both non-hematopoietic and
hematopoietic sources of TF, respectively, prevented the
activation of coagulation by heme in vivo (Figure 5C). 
Effect of hemopexin treatment on plasma TAT levels in
sickle cell mice
In sickle cell disease and other hemolytic anemias, plas-
ma hemopexin levels are depleted by the excess circulat-
ing heme. We hypothesized that excess free heme can
contribute to the hypercoagulable state observed in sickle
cell disease. Therefore, we investigated whether increas-
ing the hemopexin levels in the circulation could attenuate
coagulation in a mouse model of sickle cell disease.
Consistent with our previous study,25 plasma TAT levels
were significantly elevated in sickle cell mice compared to
non-sickle controls (Figure 6). Administration of hemopex-
in into sickle mice resulted in a 30% decrease of plasma
TAT levels; however, this change was not statistically dif-
ferent from TAT levels in vehicle-treated sickle mice
(Figure 6). This partial reduction in plasma TAT levels sug-
gests that free heme might play a minor role in the hyper-
coagulable state observed in sickle cell mice. 
Discussion
We have demonstrated that an excess of circulating free
heme can deplete plasma hemopexin levels and trigger
systemic thrombin generation in wild-type mice.
Furthermore, using both pharmacological and genetic
approaches, we found that heme-mediated coagulation
Heme and activation of coagulation
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Figure 3. Heme induces tissue factor (TF) expression and activity on
leukocytes. (A) Procoagulant activity of RAW 264.7 mouse
macrophages treated with the indicated dose of heme for 6 h (n=3).
(B) Procoagulant activity of human PBMCs treated with the indicated
dose of heme for 24 h (n=4). Data are the mean fold change versus
vehicle-treated cells, represented as mean±SEM. **P<0.01 versus
0 mM heme. (C) TF staining (brown) on white blood cells isolated from
mice 6 h after heme injection. (D) TF staining (brown) on human
PBMCs treated ex vivo with 10 mM heme for 24 h.
Figure 4. Tissue factor (TF) expression in lung after administration of
heme. Representative lung sections demonstrating TF expression in
vehicle- and heme-treated mice. TF stains as brown. Low magnifica-
tion images are 400X, and insets are 400% larger than originals. BR:
bronchus; PA: pulmonary artery; SPA: small pulmonary artery; PV:
pulmonary vein; Lum: lumen of vessel. Arrowheads indicate epithe-



























activation was TF-dependent. It is known that TF expres-
sion can be up-regulated on leukocytes during many dis-
eases. Therefore, to identify the cellular sources of TF that
contribute to heme-mediated activation of coagulation in
vivo, we first determined whether heme is capable of
inducing TF expression on mouse leukocytes. Indeed,
heme treatment caused a dose-dependent increase in pro-
coagulant activity in a mouse macrophage cell line, and
TF-positive leukocytes were isolated from heme-treated
mice. Despite that, we did not observe an increase in TF-
dependent PCA in leukocytes isolated from heme-treated
mice (data not shown). The reasons for not seeing the
increase in TF-dependent PCA are the very small number
of TF-positive monocytes in the heme-treated mice, and
the possibility that TF-positive leukocytes become activat-
ed, migrate outside the vessels, and, therefore, cannot be
isolated from blood. In fact, we occasionally observed TF-
positive, monocyte-like cells in the lung sections from
heme-treated mice (data not shown). Furthermore, heme
treatment also increased PCA and TF expression on
human PBMCs. These data indicate that excess free heme
can up-regulate TF expression on leukocytes. Consistent
with these findings, we previously showed that in sickle
cell disease, monocyte TF expression is positively correlat-
ed with markers of hemolysis and coagulation activation.11
Surprisingly, deletion of TF from all myeloid cells had no
effect on heme-induced coagulation activation in mice,
indicating that leukocytes are not the dominant source of
TF in these experimental conditions. 
Since others have demonstrated that heme induces TF
expression and activity on endothelial cells in vitro,13 we
first tested whether heme can induce endothelial TF
expression in vivo. We focused on the lung vasculature,
because it has been reported to be the only vascular bed
demonstrating increased TF staining by endothelial cells in
mouse models of sickle cell disease.15 However, we did not
observe any TF-positive endothelial cells in the lung vas-
culature of mice treated with heme. Consistent with this
result, combined deficiency of TF in both hematopoietic
and ECs did not attenuate heme-mediated activation of
coagulation. These data suggest that the increased expres-
sion of endothelial cell TF observed in sickle cell mice is
not mediated only by free heme. However, we cannot
exclude that induction of TF in lung endothelial cells
requires prolonged exposure to free heme. Further studies
should determine the mechanism of increased TF expres-
sion by lung ECs in sickle cell mice. 
The fact that deletion of TF from both endothelial and
hematopoietic cells did not attenuate heme-dependent
coagulation activation led us to hypothesize that heme
may damage the vascular endothelium and expose
extravascular sources of TF. Indeed, we found increased
vascular permeability in the heart, lung and kidneys of
heme-treated mice. However, inhibition of the non-
hematopoietic source of TF alone had no effect on coagu-
lation activation induced by heme. It was only when both
non-hematopoietic and hematopoietic cell TF were inhib-
E.M. Sparkenbaugh et al.
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Figure 5. Role of myeloid, hematopoietic and endothelial cell tissue
factor (TF) in coagulation activation. (A) Plasma TAT levels in TFflox/flox,
LysM Cre– or TFflox/flox, LysM Cre+ mice 6 h after vehicle or heme 
(35 mmol/kg) injection (n=5-11). (B) Plasma TAT levels 6 h after vehi-
cle or heme injection in TFflox/flox, Tie-2 Cre-  or TFflox/flox, Tie-2 Cre+ mice
(n=5-8). (C) Plasma TAT levels 6 h after vehicle vehicle or heme injec-
tion in HTFBM/WT mice treated with rat IgG (10 mg/kg), 1H1 (20
mg/kg) or HTF-1/1H1 (10 mg/kg and 10 mg/kg, IP) antibodies
(n=5-11/group). Data are presented as mean±SEM. *P<0.05,
**P<0.01, ***P<0.001.  Asterisks above the bar indicate signifi-
cance versus vehicle/IgG-treated group; asterisks over line indicate
significance between two groups.
Figure 6. Hemopexin attenuates coagulation activation in sickle cell
mice. Five-month old male Berkley sickle cell mice (mα–/–, mβ–/–,
hβSS) were administered saline or hemopexin (280 μmol/kg intra-
venous) twice a week for two weeks, and plasma TAT levels were
analyzed 16 h after the last injection (n=6-13). Data are presented








































ited that coagulation activation was attenuated. These
data suggest that both monocyte and perivascular TF con-
tribute to heme-mediated coagulation activation in vivo.
Importantly, the data presented here differ from observa-
tions in a mouse model of endotoxemia, where LPS-
induced coagulation activation was partially attenuated by
inhibition of either hematopoietic or non-hematopoietic
sources of TF.16 This difference is most likely explained by
the fact that the level of coagulation activation in endotox-
emic mice was much greater than in heme-treated mice,
which allowed us to reveal the partial contribution of TF
expressed by both cell types.29
It has recently been proposed that in addition to cellular
TF, procoagulant microparticles (MPs) may contribute to
the propagation of coagulation in various pathological
conditions.30,31 MPs are small membrane vesicles released
from activated or apoptotic cells. The procoagulant prop-
erties of MPs are due to the presence of phosphatidylser-
ine (PS) with or without TF on their surface.30 Platelet- and
erythrocyte-derived MPs, which are TF negative, con-
tribute to thrombin generation in a FXII/FXI-dependent
manner, whereas thrombin generation induced by TF-pos-
itive leukocyte-derived MPs requires FVII but not FXII.32,33
In our dose titration and time course experiment, we did
not observe any increase in the total number of PS-posi-
tive MPs at 1, 3 or 6 h after heme treatment (data not
shown), which may explain the lack of FXI contribution to
the heme-induced activation of coagulation. Furthermore,
it is unlikely that increased levels of free heme can lead to
the activation of FXII because treatment of heme-injected
mice with 14E11 antibody (an inhibitor of FXIIa-mediated
activation of FXI), had no effect on plasma TAT levels.
These data strongly support the notion that heme-induced
coagulation activation is predominantly driven by TF.
Excess heme has been linked to the pathology of a vari-
ety of hemolytic anemias. To examine if the excess of
heme can contribute to the activation of coagulation in
sickle cell disease, we treated sickle cell mice with recom-
binant hemopexin. Treatment with hemopexin partially
attenuated coagulation activation in sickle cell mice, sug-
gesting that the excess of circulating heme in sickle cell
mice might contribute to the hypercoagulable state. Our
data contribute to a growing body of evidence suggesting
that restoring hemopexin levels in sickle cell mice can be
beneficial. Ghosh and colleagues showed that excess
heme causes acute chest syndrome in sickle cell mice, and
that administration of hemopexin, to reduce plasma levels
of free heme, protected sickle mice from acute chest syn-
drome.28 Restoring hemopexin also suppressed heme-
mediated liver congestion,6 endothelial activation, oxida-
tive stress and cardiovascular dysfunction in sickle cell
mice.3 Finally, hemopexin attenuated vascular stasis and
vaso-occlusion in sickle cell mice.20 These findings all
implicate that administration of hemopexin might have
therapeutic potential for sickle cell patients.
Heme has also been suggested to have anticoagulant
properties. Recently, it has been shown that heme can
bind FVIII in vitro and inhibit its procoagulant properties.34
However, heme could only inhibit the procoagulant func-
tions of FVIII when administered in a molar excess and in
the absence of von Willebrand Factor (VWF) which is a
natural chaperone of FVIII.34 This suggests that an excess
of heme might have an anticoagulant effect, but this
remains to be tested in vivo. However, Belcher and col-
leagues recently demonstrated that heme rapidly triggers
the release of VWF from EC both in vitro and in vivo,20
which would diminish the anticoagulant properties of
heme and support the procoagulant role that we observed.
In summary, our data indicate that an excess of heme
promotes systemic thrombin generation in mice that is
dependent on the extrinsic coagulation pathway but not
the intrinsic pathway. Furthermore, we demonstrate that
excess heme can increase TF expression and procoagulant
activity on leukocytes both in vitro and in vivo, and that
heme increases vascular permeability and exposes
extravascular TF. Using cell-type specific knockouts and
chimeric mice, we showed that mice are protected from
heme-induced coagulation activation only when all cellu-
lar sources of TF are inhibited. Finally, we demonstrated
that hemopexin partially attenuated thrombin generation
in sickle cell mice, suggesting that excess heme influences
coagulation, and might contribute in part to the thrombot-
ic complications of sickle cell disease.
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